
USA - New York Stock Exchange - NYSE:VRX - CA91911K1021
The current stock price of VRX is 23.4 null. In the past month the price decreased by -12.69%. In the past year, price increased by 35.73%.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.
VALEANT PHARMACEUTICALS INTL I
2150 ST. ELZEAR BLVD. WEST
LAVAL A8 H7L 4A8
CEO: Joseph C. Papa
Phone: 514-744-6792
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.
The current stock price of VRX is 23.4 null. The price decreased by -3.43% in the last trading session.
VRX does not pay a dividend.
VRX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
You can find the ownership structure of VALEANT PHARMACEUTICALS INTL I (VRX) on the Ownership tab.
ChartMill assigns a technical rating of 6 / 10 to VRX. When comparing the yearly performance of all stocks, VRX is one of the better performing stocks in the market, outperforming 90.59% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to VRX. While VRX is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months VRX reported a non-GAAP Earnings per Share(EPS) of 3.96. The EPS decreased by -29.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -10.65% | ||
| ROA | -2.56% | ||
| ROE | -20.27% | ||
| Debt/Equity | 5.59 |